[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"idiopathic-nephrotic-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:idiopathic-nephrotic-syndrome":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100378440","a-national-prospective-cohort-of-patients-with-idiopathic-nephrotic-syndrome-beginning-in-childhood-100378440",false,"NCT04207580","A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.","PIN'SNP","Inclusion Criteria:\n\n* Patient under 18 years of age\n* With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018\n* Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology\n* Residing in France\n* Consent signed by parents and patient's agreement to participate (if of age)\n* Affiliated to a social security system.\n\nExclusion Criteria:\n\n* Refusal of the patient or legal representatives to participate in the cohort","ALL","18 Years",{"count":19,"type":20},1180,"ESTIMATED","OBSERVATIONAL","Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies.\n\nThe main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.",[24],"Idiopathic Nephrotic Syndrome",[26],"Cohort - Idiopathic nephrotic syndrome - child","RECRUITING","2026-03-11",{"date":30,"type":31},"2026-03-13","ACTUAL",{"date":33,"type":31},"2020-03-13",{"date":35,"type":20},"2048-01",{"name":37,"class":38},"University Hospital, Limoges","OTHER",48,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100358661","the-forme-registry-the-german-focal-segmental-glomerulosclerosis-and-minimal-change-disease-registry-100358661","NCT03949972","The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)","FOrMe","Inclusion Criteria (cohort A):\n\n* written informed consent\n* 17 or less years of age\n* idiopathic nephrotic syndrome\n\nInclusion Criteria (cohort B):\n\n* written informed consent\n* older or equal to 18 years of age\n* biopsy-proven primary or secondary FSGS or MCD or biopsy-proven recurrence of disease in kidney transplant.\n\nExclusion Criteria (both cohorts):\n\n* Prior kidney transplant without biopsy-proven recurrence\n* A clinical diagnosis of other glomerular disease resulting in secondary MCD or FSGS as judged by the treating physicians.\n* Refusal to provide written informed consent\n* (Anticipated) incompliance with visit schedule",{"count":48,"type":20},500,"15 Years","In a monocentric, later multicentric prospective approach the FOrMe registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) aims to generate a longitudinal cohort of 150 pediatric cases of idiopathic nephrotic syndrome and 350 adult cases of biopsy-proven Minimal Change Disease (MCD) or Focal and Segmental Glomerular Sclerosis (FSGS) over 10 years. The registry will provide a repository for biomaterials such as blood samples, DNA, urine, feces, and tissue biopsies that will be accessible to collaborators to facilitate future research on pathogenesis, diagnostics, and treatment.",[52,53,24],"Glomerulosclerosis, Focal Segmental","Minimal Change Disease",[55,56,57,58,59,60],"Focal and Segmental Glomerulosclerosis","Focal & Segmental Glomerulosclerosis","FSGS","Minimal change disease","MCD","Nephrotic Syndrome","2025-09-11",{"date":63,"type":31},"2025-09-17",{"date":65,"type":31},"2018-04-01",{"date":67,"type":20},"2033-03-31",{"name":69,"class":38},"Prof. Dr. Paul Brinkkoetter",12,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100604587","phase-4-short-term-glucocorticoid-in-adult-steroid-sensitive-nephrotic-syndrome-the-coco-asteroid-study-100604587","NCT07151456","Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study","Short-term vs Conventional Glucocorticoid Therapy for the Treatment of the Initial Episode of Adult Patient With Steroid-sensitive Idiopathic Nephrotic Syndrome","Inclusion Criteria:\n\n* Urine protein: creatinine ratio ≥3000mg\u002Fg (300mg\u002Fmmol)\n* Serum\u002Fplasma albumin level \\\u003C 30g\u002FL\n* Age ≥ 16 years at the time of diagnosis\n* No prior therapy with steroids, immunosuppressive or cytotoxic agents for any form of renal disease (other than the 28 days of prednisolone therapy given initially as routine clinical practice)\n* No evidence of underlying systemic disorder or exposure to agents known to be associated with newly presenting steroid sensitive nephrotic syndrome\n* Informed consent\n* SSNS defined as Complete remission within 4 weeks of prednisone or prednisolone at standard dose\n\nExclusion Criteria:\n\n* Secondary nephrotic syndrome\n* Contradictions for glucocorticoids\n* SRNS: Lack of complete remission within 4 weeks of therapy with daily prednisone or prednisolone at standard dose\n* anti-PLA2R positive\n* Adults with histological changes other than minimal lesion or focal segmental glomerular sclerosis (FSGS) glomerulonephritis where renal biopsy has been undertaken\n* Adults with a prior history of poor compliance with medical therapy Known allergy to glucocorticoid therapy\n* Other situations where the researcher deems it inappropriate to participate in the study","16 Years",{"count":80,"type":20},224,"INTERVENTIONAL",[83],"PHASE4","This study will compare a short-term course (12 week) glucocorticoid regimen with the Conventional 24-week regimen as originally proposed by KDIGO. The purpose of the study is to determine a short-term course (12 week) of glucocorticoid decreases the time to first relapse in adults presenting with steroid sensitive nephrotic syndrome.",[24],"NOT_YET_RECRUITING","2025-08-25",{"date":89,"type":31},"2025-09-03",{"date":91,"type":20},"2026-01",{"date":93,"type":20},"2029-12",{"name":95,"class":38},"First Affiliated Hospital of Wenzhou Medical University",1]